Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|GVAX colorectal cancer vaccine||GVAX colorectal cancer vaccine is composed of irradiated colorectal cancer (CRC) cells engineered to express GM-CSF, which induces T-cell response against CRC cells (PMID: 24832153, PMID: 31876399).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01952730||Phase I||GVAX colorectal cancer vaccine||GVAX for Colorectal Cancer||Recruiting||USA||0|
|NCT01966289||Phase I||Cyclophosphamide Guadecitabine GVAX colorectal cancer vaccine||SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)||Completed||USA||0|